Encouraged but still cautious, Dan Teleman, CEO of Atox Bio Ltd., was careful not to raise expectations about the eventual outcome of the ongoing phase III ACCUTE (AB-103 Clinical Composite endpoint StUdy in necrotizing soft Tissue InfEctions), which is evaluating reltecimod (previously AB-103) in patients with necrotizing soft tissue infections (NSTIs), or so-called "flesh-eating" bacteria.